|1.||St Cyr, John A: 8 articles (09/2012 - 01/2004)|
|2.||St Cyr, John: 7 articles (11/2008 - 10/2003)|
|3.||St Cyr, J A: 5 articles (06/2015 - 02/2003)|
|4.||Boros, László G: 5 articles (01/2013 - 11/2002)|
|5.||Shecterle, Linda M: 5 articles (09/2012 - 03/2008)|
|6.||Boros, L G: 5 articles (08/2001 - 01/2000)|
|7.||MacCarter, Dean: 4 articles (05/2010 - 10/2003)|
|8.||Wei, Yan: 3 articles (10/2015 - 08/2009)|
|9.||Su, Tao: 3 articles (10/2015 - 03/2014)|
|10.||He, Rongqiao: 3 articles (10/2015 - 08/2009)|
01/01/2009 - "D-Ribose, a pentose sugar, has shown to improve myocardial high-energy phosphate stores depleted by ischemia. "
01/01/2003 - "In SHR, ribose pretreatment did not produce significant elevations in the heart's energy or improvements in tolerance to global ischemia, but significantly improved ventricular function (maximal rate of pressure rise (+dP/dt(max)), 25%; normalized contractility ((+dP/dt)/P), 13%) despite no change in hemodynamics. "
05/01/2009 - "Thus, D-ribose ameliorates the I/R-induced renal injury probably by inhibiting neutrophil activation, and may be useful in attenuating the renal injury associated with renal ischemia."
01/01/2003 - "This study determined, firstly, whether the pentose sugar ribose, previously shown to improve postischemic recovery of energy stores and function, protects against ischemia when administered as a pretreatment. "
09/01/2007 - "D-Ribose (R) has been shown to improve cardiac function and energy status after ischemia. "
09/11/2009 - "Ribose improved the ventilatory exercise status in advanced heart failure patients."
06/01/2015 - "This study investigated what role D-ribose might play in congestive heart failure patients with preserved systolic function and diastolic dysfunction. "
09/11/2009 - "As current pharmaceuticals do not address cellular energy levels, this study was designed to investigate the role of ribose on ventilation at anaerobic threshold in congestive heart failure patients. "
01/01/2004 - "Clinical trials have shown that ribose supplementation improves ischemic threshold and enhances diastolic function in congestive heart failure."
09/11/2009 - "d-ribose (5 gms/dose, tid) was assessed in 16 NYHA class III-IV, heart failure patients with VO(2), tidal volume/VCO(2), heart rate/tidal volume evaluated at 8 weeks. "
11/01/2006 - "D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy; sleep; mental clarity; pain intensity; and well-being, as well as an improvement in patients' global assessment. "
07/01/2007 - "D-ribose supplementation may prove to significantly enhance energy, sleep, mental clarity, pain control and well-being in FM patients. "
12/15/1986 - "A 55 years old patient suffering from exercise-induced muscle pain and stiffness due to primary myoadenylate deaminase deficiency has been successfully treated with D-ribose since 1984: single doses of 4 grams administered at the beginning of exercise prevented the symptoms completely; on continuation of exercise this dose had to be repeated all 10-30 min. Total doses of 50-60 g per day were tolerated without side-effects."
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
01/01/2003 - "For study 1, Sprague-Dawley rats received equal volumes of either vehicle (bolus i.v. saline) or ribose (100 mg/kg) before global myocardial ischemia. "
06/01/2010 - "However, D-ribose, a natural occurring carbohydrate, has demonstrated significant enhancing abilities in replenishing deficient cellular energy levels following myocardial ischemia, as well as improving depressed function in numerous animal investigations. "
01/01/2003 - "Thus, administration of ribose in advance of global myocardial ischemia does provide metabolic benefit in normal hearts. "
10/01/2000 - "In support of this hypothesis, recent reports have used D-ribose to increase tolerance to myocardial ischemia. "
02/01/1989 - "Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model."
01/01/2009 - "Ribose treatment reduced the infarct size and improved heart function after myocardial infarction in rats."
01/01/2009 - "In this study the effect of ribose on heart function and infarct-size was analyzed 6 h after myocardial infarction (MI) in rats. "
08/15/1967 - "Serum desoxy-ribose compounds in experimental myocardial infarction."
10/26/2001 - "Thus, 5-aminoisoquinolinone is a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase activity in cardiac myoblasts and reduces myocardial infarct size in vivo."
10/26/2001 - "5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size."
|1.||Adenosine Triphosphate (ATP)
|3.||AMP Deaminase (Myoadenylate Deaminase)
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)